Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 803 KB, PDF-dokument

Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind140
Udgave nummer5
Sider (fra-til)445-450
Antal sider6
ISSN0006-4971
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The Capital Region of Denmark, Center for Economy, provided data extracts from the EHR system. This study was supported by a COVID-19 grant from the Ministry of Higher Education and Science (0238-00006B) and the Danish National Research Foundation (DNRF126) and by the Danish Cancer Society, and the EU funded CLL-CLUE for C.U.N. C.B. received funding from Weimann's Legat. Funding support for this article was provided by the Ministry of Higher Education and Science, Denmark (0238-00006B), Danish Cancer Society, EU ERA-PERMED program (CLL-CLUE), Danish National Research Foundation (DNRF126).

Funding Information:
This study was supported by a COVID-19 grant from the Ministry of Higher Education and Science (0238-00006B) and the Danish National Research Foundation (DNRF126) and by the Danish Cancer Society, and the EU funded CLL-CLUE for C.U.N. C.B. received funding from Weimann's Legat. Funding support for this article was provided by the Ministry of Higher Education and Science, Denmark (0238-00006B), Danish Cancer Society, EU ERA-PERMED program (CLL-CLUE), Danish National Research Foundation (DNRF126).

Publisher Copyright:
© 2022 American Society of Hematology

Links

ID: 323844906